Promising new drug targets devastating infant seizures
NCT ID NCT07019922
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 35 times
Summary
This study tests a new medicine called elsunersen in 50 children with a rare genetic epilepsy caused by changes in the SCN2A gene. The goal is to see if the drug can safely reduce the number of seizures. Children must have had seizures before 3 months of age and currently have at least 4 seizures per month to join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPTIC ENCEPHALOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Praxis Research Site
RECRUITINGSan Diego, California, 92123, United States
-
Praxis Research Site
RECRUITINGChicago, Illinois, 60612, United States
-
Praxis Research Site
RECRUITINGPorto Alegre, 90035, Brazil
-
Praxis Research Site
RECRUITINGSão Paulo, 05403, Brazil
Conditions
Explore the condition pages connected to this study.